seasonal influenza vaccine (mRNA-1020) / Moderna 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  mRNA-1083 / Moderna, seasonal influenza vaccine (mRNA-1020) / Moderna
    Review, Journal:  Comparing Moderna's mRNA-1083 and Pfizer's dual-target mRNA vaccines for influenza and COVID-19. (Pubmed Central) -  May 25, 2025   
    Both utilize mRNA technology, demonstrating strong immunogenicity and favorable safety profiles. Moderna's mRNA-1083 showed superior immune responses, while Pfizer's mRNA-1020/1030 performed well but was slightly less effective against influenza B. These vaccines simplify immunization strategies, enhance protection, and emphasize the need for global vaccine equity to prevent future outbreaks.
  • ||||||||||  seasonal influenza vaccine (mRNA-1020) / Moderna, seasonal influenza vaccine (mRNA-1030) / Moderna
    Trial completion:  A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults (clinicaltrials.gov) -  Dec 7, 2022   
    P1/2,  N=572, Completed, 
    Moderna's mRNA-1083 showed superior immune responses, while Pfizer's mRNA-1020/1030 performed well but was slightly less effective against influenza B. These vaccines simplify immunization strategies, enhance protection, and emphasize the need for global vaccine equity to prevent future outbreaks. Active, not recruiting --> Completed
  • ||||||||||  seasonal influenza vaccine (mRNA-1020) / Moderna, seasonal influenza vaccine (mRNA-1030) / Moderna
    Enrollment closed:  A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults (clinicaltrials.gov) -  Nov 14, 2022   
    P1/2,  N=572, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting